Browsing Tag
azer-cel
2 posts
Is Imugene’s 17% stock slump an overreaction to dilution or a warning sign for CAR T investors?
Imugene shares fell 17% after a $37.5M raise, but can Fast Track and strong azer-cel data make the drop a buying opportunity for CAR T investors?
Imugene’s A$37.5m capital raise fuels pivotal azer-cel trial plans as stock tumbles 17%
Imugene raises A$37.5M to fund pivotal azer-cel trial in 2026. Can its off-the-shelf CAR T therapy deliver on its $2B market promise?